CJC-1295/Ipamorelin
CJC-1295 (no DAC) + Ipamorelin blend
CJC-1295 (no DAC / Modified GRF 1-29) and Ipamorelin are commonly marketed together as a GH-secretagogue stack. CJC-1295 (no DAC) binds the pituitary GHRH receptor and Ipamorelin selectively activates GHS-R1a without meaningful cortisol or prolactin elevation (Raun et al., 1998). GHRH + GHRP synergy for amplifying pulsatile GH release is an established concept in human physiology studies of other pairs (e.g., GHRH + GHRP-2; Veldhuis & Bowers, 2009), but the specific CJC-1295 (no DAC) + Ipamorelin combination has not been tested in a controlled human efficacy trial. Grey-market dosing (commonly 100mcg CJC-1295 + 200–300mcg Ipamorelin SubQ before bed) is not clinically validated. IMPORTANT: this blend uses CJC-1295 WITHOUT DAC only — the DAC form is a different, long-acting molecule and must not be substituted.
Typical dose
300mcg
Cycle
8-12 weeks